Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Franklin Genomic Advancements Fund A (acc) EUR-H1 Fonds 116503668 / LU2441052540

6.73 EUR
-0.11 EUR
-1.61 %
11.2.2025
NAV

Nettoinventarwert (NAV)

6.73 EUR -0.11 EUR -1.61 %
Vortag 6.84 EUR Datum 11.02.2025

Franklin Genomic Advancements Fund A (acc) EUR-H1 Fonds Kurs - 1 Jahr

  • 1W
  • 3M
  • 1J
  • 3J
  • 5J
  • MAX

Top Kryptowährungen ETPs

Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 315.17%
21Shares Stacks Staking ETP CH1258969042 227.84%
21Shares Stellar ETP CH1109575535 197.58%
21Shares The Sandbox ETP CH1177361008 134.26%
21Shares Algorand ETP CH1146882316 102.35%
21Shares Sui Staking ETP CH1360612159 1.41%
21Shares Immutable ETP CH1360612142 -28.94%
21Shares Injective Staking ETP CH1360612134 -42.95%
Name ISIN Performance
21Shares Sui Staking ETP CH1360612159 356.06%
21Shares Ripple XRP ETP CH0454664043 321.18%
21Shares Stellar ETP CH1109575535 227.84%
21Shares Aave ETP CH1135202120 159.59%
21Shares Stacks Staking ETP CH1258969042 145.10%
21Shares Algorand ETP CH1146882316 145.06%
21Shares Injective Staking ETP CH1360612134 -6.42%
21Shares Immutable ETP CH1360612142 -27.24%
Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 361.82%
21Shares Stellar ETP CH1109575535 190.21%
21Shares Aave ETP CH1135202120 182.07%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 164.76%
21Shares Bitcoin Core ETP CH1199067674 105.26%
Name ISIN Performance
21Shares Solana staking ETP CH1114873776 900.73%
21Shares Ripple XRP ETP CH0454664043 520.30%
21Shares Bitcoin Core ETP CH1199067674 346.13%
21Shares Bitcoin ETP CH0454664001 334.85%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 313.39%

Fundamentaldaten

Valor 116503668
ISIN LU2441052540
Emittent Franklin Templeton International Services
Aufgelegt in Luxembourg
Auflagedatum 08.02.2022
Kategorie Branchen: Andere Sektoren
Währung EUR
Volumen 3’200’331.23
Depotbank J.P. Morgan SE, Luxembourg Branch
Geschäftsjahresende 30.06.
Berichtsstand 10.02.2025

Anlagepolitik

So investiert der Franklin Genomic Advancements Fund A (acc) EUR-H1 Fonds: The Fund's investment objective is capital appreciation. The Fund invests principally in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. Equity securities generally entitle the holder to participate in a company's general operating results. While the Fund invests predominantly in common stocks, it could also invest in preferred stock, convertible securities and warrants on securities.

ETP Performance: Franklin Genomic Advancements Fund A (acc) EUR-H1 Fonds

Performance 1 Jahr
-6.53
Performance 2 Jahre
-11.56
Performance 3 Jahre -
Performance 5 Jahre -
Performance 10 Jahre -